Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely align with the prescribing information for bortezomib (BORUZU) across indications, dosing regimens, combination therapies, safety concerns (notably peripheral neuropathy and hematologic effects), and monitoring considerations. Minor branding naming differences are noted, and there are no material contradictions identified. Some label sections (e.g., contraindications, boxed warnings, pregnancy/pediatric use) are not addressed in the claims, representing potential omissions.
Category Scores
Accurate Statements
Bortezomib (brand name Velcade) is used to treat multiple myeloma.
Indication 1.1; Brand naming note: label uses BORUZU; Velcade is a brand name.
Bortezomib is used to treat mantle cell lymphoma in adults who have had at least one prior therapy.
Indication 1.2; 2.6
Bortezomib inhibits the proteasome, a protein complex cells use to break down damaged or unwanted proteins.
12.1
Blocking the proteasome can trigger cancer cell death, especially in multiple myeloma and mantle cell lymphoma cells.
12.1
Bortezomib is used in adults with multiple myeloma.
1.1
Bortezomib is used in adults with relapsed or refractory mantle cell lymphoma after prior treatment.
1.2; 2.6
The exact combination depends on the cancer type and treatment line.
2.1; 2.2; 2.4
Bortezomib is often used in combination with other medicines for multiple myeloma.
2.2; 2.6
Bortezomib is commonly given with other anti-cancer drugs as part of combination regimens for multiple myeloma.
2.2; 2.6
Bortezomib is commonly given with other anti-cancer drugs as part of combination regimens for some lymphoma settings.
2.4
Common concerns include side effects related to blood counts.
5.7
Common concerns include side effects related to nerves.
5.7; 6.1
Peripheral neuropathy (nerve damage causing tingling or numbness) is a known risk.
5.7; 6.1
Clinicians monitor for peripheral neuropathy closely.
2.7; 5.7
Clinicians adjust dosing if needed due to peripheral neuropathy.
2.7
Unsupported Statements
Contradictions
Important Omissions
Pregnancy risk information and contraception recommendations.
Importance:
Moderate
Pediatric safety and use information.
Importance:
Moderate
Contraindications section content.
Importance:
Moderate
Boxed warnings and warnings/precautions wording.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Note brand name terminology and explicitly address contraindications, boxed warnings, and pregnancy/pediatric use sections to ensure comprehensive alignment.